Prof Martin Reck speaks to ecancer about digital pathology (DP) versus manual SP263 PD-L1 tumour cell (TC) scoring on whole imaging slides from patients with stage II-IIIA PD-L1 TC ≥50% NSCLC.

The IMpower010 trial investigates the use of adjuvant atezolizumab in early-stage non-small cell lung cancer.

Following chemotherapy, patients with PD-L1-expressing tumours experience better disease-free and overall survival rates.

An innovative AI algorithm evaluates PD-L1 expression, identifying more high expression cases than traditional pathology, while both methods show similar efficacy.

This advancement could improve patient selection for atezolizumab treatment in Europe.